279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry

BACKGROUND: Dalbavancin, a long-acting lipoglycopeptide approved by the US FDA and EMA for acute bacterial skin and skin structure infections (ABSSSI) has potent activity against Gram-positive pathogens including MRSA. A total of 39 of 39 patients with baseline S aureus bacteremia from previous stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez, Pedro, Rappo, Urania, McGregor, Jennifer, DiPompo-Day, Lisa, McCarthy, Matthew W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778206/
http://dx.doi.org/10.1093/ofid/ofaa439.323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778206/
http://dx.doi.org/10.1093/ofid/ofaa439.323

Ejemplares similares